Vericel Corp
Vericel Corporation (Nasdaq: VCEL) develops, manufactures and commercializes cell therapies and specialty biologic products for sports medicine and severe burn care. Its portfolio includes MACI, an autologous cellularized scaffold made from a patient’s cartilage cells for repairing full-thickness cartilage defects of… From the company’s description.
Over the twelve months to Sep 30, 2026, Vericel Corp reported revenue of $324.17M, up 25.3% from a year earlier, and net income of $33.31M. Its operating margin was 8.3%, and operations generated $65.31M in cash. In fiscal 2025, it reported revenue of $276.26M, up 16.5% from fiscal 2024, and net income of $16.52M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vericel Corp does
In the company’s own words
Vericel Corporation (Nasdaq: VCEL) develops, manufactures and commercializes cell therapies and specialty biologic products for sports medicine and severe burn care. Its portfolio includes MACI, an autologous cellularized scaffold made from a patient’s cartilage cells for repairing full-thickness cartilage defects of the knee, and MACI Arthro, which enables arthroscopic delivery using custom instruments. Vericel also sells biopsy kits used in MACI treatment. Epicel is a cultured skin-cell replacement for adult and pediatric patients with extensive deep-dermal or full-thickness burns. NexoBrid, commercialized in North America under an exclusive license and supply agreement with MediWound, is an enzyme-based product for removing eschar from thermal burns. The company’s two commercial teams focus on MACI and burn care, serving orthopedic surgeons, hospitals and specialized burn centers; it sells NexoBrid to specialty distributors. MACI and Epicel are manufactured in Massachusetts, while MediWound manufactures NexoBrid. Vericel’s marketed portfolio includes two FDA-approved autologous cell therapies and one FDA-approved specialty biologic.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 887359
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vericel Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vericel Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vericel Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vericel Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vericel Corp's last four quarterly filings that the numbers alone won't show?”